SCHEMBL893038

SCHEMBL893038

N#Cc1ccc(N2CCC(C(=O)NCCc3c[nH]c4ccc(Cl)cc34)C2=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SNCA P37840 9/20 0.56
MAPT P10636 3/20 0.54
MTNR1A P48039 1/20 0.49
MTNR1B P49286 1/20 0.49
MMP9 P14780 1/20 0.48
MMP8 P22894 1/20 0.48
MMP14 P50281 1/20 0.48
TSHR P16473 1/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46
SPR P35270 1/20 0.45
KDM4E B2RXH2 1/20 0.45
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL892580 0.92 MTNR1A (0.55) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL10274768 0.90 MTNR1A (0.53) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL892306 0.89 SNCA (0.54) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL892859 0.89 SNCA (0.54) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL892573 0.89 LMNA (0.55) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL892549 0.87 MTNR1A (0.52) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL892093 0.87 MTNR1A (0.52) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL891522 0.87 MTNR1A (0.55) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL892984 0.87 MTNR1A (0.53) SNCAMTNR1AMTNR1BMMP9MMP8
SCHEMBL891901 0.87 SNCA (0.57) SNCAMTNR1AMTNR1BMMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12178805-B2 Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders REMYND N.V. (BE) 2024-12-31 US disclosed
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2020-08-13 US disclosed
EP-3634407-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2020-04-15 EP disclosed
EP-3190109-B1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV LEUVEN KATH (BE) 2020-02-19 EP disclosed
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases REMYND (BE) 2019-02-21 US disclosed
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases REMYND (BE) 2019-02-21 US disclosed
WO-2018206757-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2018-11-15 WO disclosed
US-10117850-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2018-11-06 US disclosed
EP-3190109-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven (BE) 2017-07-12 EP disclosed
EP-2440550-B1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV LEUVEN KATH (BE) 2017-03-15 EP disclosed
US-9434722-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2016-09-06 US disclosed
US-9434722-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2016-09-06 US disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-8618138-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2013-12-31 US disclosed
EP-2440550-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-04-18 EP disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
WO-2010142801-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN SNCA 1/4885MAPT 2/4885MTNR1A 67/4885
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN SNCA 1/4885MAPT 2/4885MTNR1A 61/4885
US-20190054068-A1 Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases SNCA, MAPT, NLN SNCA 1/4885MAPT 2/4885MTNR1A 67/4885
US-10117850-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases SNCA, MAPT, NLN SNCA 1/4885MAPT 2/4885MTNR1A 61/4885
US-12178805-B2 Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders PDE4A, PDE12, PDE2A SNCA 294/4885MAPT 68/4885MTNR1A 1212/4885
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS PDE4A, PDE12, PDE2A SNCA 294/4885MAPT 68/4885MTNR1A 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.